Ipamorelin Peptide Calculator

Ipamorelin is a synthetic pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib denotes α-aminoisobutyric acid and D-2-Nal denotes D-2-naphthylalanine. Its molecular weight is approximately 711.9 Da, placing it firmly in the small-peptide range—a size that contributes to its rapid dissolution in bacteriostatic water and its relatively short circulating half-life. It was first described by Raun et al. in 1998 as a growth hormone secretagogue with a superior selectivity profile compared to predecessors in the GHRP family.

The non-natural amino acid substitutions (D-2-Nal at position 3, D-Phe at position 4, and the C-terminal amide) are pharmacological design features. D-amino acids are resistant to proteolytic degradation by peptidases that recognize only the natural L-configuration, extending Ipamorelin's stability in biological media. The C-terminal amide prevents carboxypeptidase cleavage. Together, these modifications extend the effective research window following administration compared to the endogenous ghrelin peptide.

Selective Ghrelin Mimetic: GHS-R1a Agonism

Ipamorelin's primary mechanism is agonism at the growth hormone secretagogue receptor 1a (GHS-R1a), a Gq/11 protein-coupled receptor expressed at highest density on somatotrophs in the anterior pituitary gland and on neurons in the hypothalamic arcuate nucleus. GHS-R1a is the cognate receptor for the endogenous hormone ghrelin, a 28-amino acid orexigenic peptide produced predominantly in the stomach. Ipamorelin mimics ghrelin's receptor-activating conformation while lacking ghrelin's octanoyl fatty acid modification—the structural feature responsible for ghrelin's off-target effects on appetite and cortisol.

Pulsatile GH Release from Pituitary Somatotrophs

When Ipamorelin binds GHS-R1a on pituitary somatotrophs, it activates phospholipase C via Gq/11, leading to inositol-1,4,5-trisphosphate (IP3) generation and diacylglycerol (DAG) production. IP3-mediated calcium release from the endoplasmic reticulum, combined with DAG-activated protein kinase C (PKC), triggers exocytosis of pre-formed GH secretory granules. The result is a discrete, pulsatile GH release event—reflecting and amplifying the normal episodic GH secretion pattern rather than inducing a sustained elevation that would suppress endogenous pituitary sensitivity.

High Selectivity: Why ACTH, Cortisol, and Prolactin Are Spared

The defining pharmacological characteristic of Ipamorelin versus earlier GHRPs is its exceptional selectivity for GHS-R1a-mediated GH release. GHRP-6 and GHRP-2 activate not only GHS-R1a but also interact with non-specific receptors on corticotrophs (triggering ACTH and cortisol release) and on lactotrophs (triggering prolactin release). These off-target activations complicate data interpretation and introduce confounding variables in GH-axis research. Ipamorelin's structural geometry—particularly the D-2-Nal and D-Phe residues—confers shape complementarity to GHS-R1a while producing minimal activation of ACTH, cortisol, or prolactin pathways at doses producing maximal GH release. This selectivity makes Ipamorelin the preferred tool when researchers need an isolated readout of somatotroph function.

Common Research Vial Sizes

• 2mg vials: the most widely used format for Ipamorelin research. Ideal for studies using 100–200mcg dose ranges, providing 10–20 research doses from a single vial when prepared at standard concentration.
• 5mg vials: preferred for longer-duration protocols or combination studies (e.g., with CJC-1295) where a larger total peptide mass is required to cover the full study period without re-reconstitution.

Ipamorelin Dosage Chart: Calculation Example

The Ipamorelin calculator above uses the standard concentration formula. The most common reference preparation is the 2mg vial with 2ml BAC water:

Handling: Protecting a Delicate Pentapeptide

Ipamorelin's small molecular size (MW ~711 Da) contributes to rapid dissolution but also makes it more susceptible to degradation from physical and thermal stress than larger, more structurally complex peptides. Key handling principles for maintaining peptide integrity:

1. 1Temperature equilibration: Allow the lyophilized vial to reach room temperature (15–20 minutes) before reconstitution. Injecting cold BAC water into a cold vial increases the risk of incomplete dissolution and localized concentration gradients that promote aggregation.
2. 2Alcohol swab and dry time: Disinfect the rubber stopper with a 70% isopropyl alcohol swab and allow it to air dry fully. Residual alcohol entering the vial can denature small peptides.
3. 3Slow wall injection: Direct the BAC water stream against the inner glass wall, not the lyophilized cake. High-velocity contact with the powder is a primary cause of mechanical denaturation in small peptides.
4. 4No vortexing or vigorous shaking: Ipamorelin is sensitive to interface-induced denaturation at the air-liquid boundary created by shaking. Gentle swirling or rolling is sufficient—the peptide dissolves within seconds under careful technique.
5. 5Minimize stopper punctures: Each needle insertion is a potential contamination event. Calculate all dose volumes using the Ipamorelin calculator before the first draw to minimize the number of stopper punctures per vial.

Muscle Mass Preservation and Anabolic Signaling

The GH pulse induced by Ipamorelin stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which in turn activates the PI3K-Akt-mTOR signaling cascade in skeletal muscle. In animal models of age-related sarcopenia and glucocorticoid-induced muscle wasting, Ipamorelin administration has been associated with preservation of lean body mass and attenuation of muscle protein degradation. These findings have motivated research into its potential utility in models of cachexia and post-surgical muscle recovery.

Bone Mineral Density

GH and IGF-1 are well-established regulators of bone remodeling, stimulating osteoblast differentiation and collagen matrix synthesis. Preclinical studies using Ipamorelin in aged rat models have demonstrated measurable increases in bone mineral content and trabecular bone density compared to controls, supporting its investigation as a tool in osteoporosis research. The pulsatile GH delivery pattern—more physiological than continuous infusion—may be important for optimal bone response, as osteoblast GH receptor sensitivity is partially regulated by intermittent, rather than sustained, GH exposure.

Sleep Architecture and Nocturnal GH Secretion

The largest endogenous GH pulse in humans and rodents occurs during slow-wave sleep (SWS), driven by hypothalamic GHRH release. Research protocols examining Ipamorelin's interaction with sleep-stage GH secretion have demonstrated amplification of the nocturnal GH peak in animal models. This has made Ipamorelin a subject of study in sleep quality research, where GH secretion is used as an objective marker of deep-sleep architecture quality. Studies in aged animals—where both SWS quality and nocturnal GH amplitude decline—have shown partial restoration of this nocturnal GH pattern with Ipamorelin administration.

Saturation Dose Concept in Research Literature

Published Ipamorelin research frequently discusses 'saturation doses'—the dose level at which GHS-R1a occupancy is sufficiently high that further dose escalation produces no proportional increase in GH output. Animal model data suggests this saturation threshold approximates 100–200mcg per kg body weight for subcutaneous administration. Doses above this range do not meaningfully augment peak GH, making them pharmacologically redundant. This concept is important for research protocol design: once the saturation dose is established in a given animal model, escalation beyond it increases cost and potential side-effect burden without improving the GH readout.

• Lyophilized powder at −20°C: Stable for up to 24 months. Recommended for long-term research stock. Store in single-use aliquots where possible to eliminate repeat temperature cycling.
• Lyophilized powder at 2–8°C: Stable for up to 6 months. Appropriate for active research batches accessed regularly over a short study window.
• Reconstituted solution at 2–8°C: Use within 28 days. Bacteriostatic water (containing 0.9% benzyl alcohol) maintains sterility and provides mild antimicrobial protection, but does not prevent peptide degradation indefinitely.
• pH sensitivity: Solution-phase Ipamorelin stability is pH-dependent. The optimal pH range for long-term peptide stability in solution is approximately 4.5–6.0. Bacteriostatic water (pH ~5.5) falls within this range, which is one reason it is preferred over sterile saline (pH ~7.0) for reconstitution. Higher pH accelerates hydrolysis of the peptide backbone, particularly at aspartate residues.
• Do not freeze reconstituted solution: Ice crystal formation physically disrupts the peptide structure and can denature the D-amino acid residues integral to Ipamorelin's receptor-binding geometry.
• Light exposure: Protect from UV and direct light. The D-2-naphthylalanine residue (D-2-Nal) contains an aromatic naphthyl ring that can undergo photo-oxidation under UV exposure, altering the peptide's binding affinity for GHS-R1a.

Does Ipamorelin cause hunger like GHRP-6?

Significantly less. GHRP-6's orexigenic (appetite-stimulating) effect is a well-documented off-target consequence of its interaction with non-GHS-R1a receptors, including ghrelin receptor isoforms expressed in hypothalamic feeding circuits and vagal afferents. GHRP-6's appetite stimulation is often strong enough to be a confounding variable in body composition research. Ipamorelin's superior selectivity for the pituitary GHS-R1a subtype, combined with the absence of fatty acid modification (which is responsible for much of ghrelin's orexigenic signaling), results in a dramatically reduced hunger signal. In animal studies comparing the two compounds at GH-equivalent doses, Ipamorelin demonstrates negligible effects on food intake, making it a cleaner research tool for studies where appetite is not the target variable.

Why is Ipamorelin often combined with CJC-1295 in research?

The combination targets two complementary nodes of the GH secretory axis, producing a synergistic effect greater than either compound alone. Ipamorelin acts at the GHS-R1a receptor (the ghrelin receptor) on somatotrophs, triggering pulsatile GH release via calcium-dependent exocytosis. CJC-1295 (with DAC) acts at the GHRH receptor on the same somatotrophs, stimulating GH gene transcription and synthesis while amplifying the amplitude of the release pulse. These are mechanistically distinct pathways that converge on the same output—GH secretion—but through different intracellular signaling cascades (Gq/11-IP3-calcium for Ipamorelin; Gs-adenylyl cyclase-cAMP-PKA for CJC-1295/GHRH). Activating both simultaneously produces a multiplicative, rather than additive, increase in GH output in rodent models.

How does the Ipamorelin calculator determine units from a dosage in mcg?

The Ipamorelin calculator divides the target dose in mcg by the concentration per unit derived from your vial size and BAC water volume. For example: a 2mg vial reconstituted with 2ml BAC water yields a concentration of 10mcg/unit. A 100mcg target dose requires 100 ÷ 10 = 10 units on a standard U-100 insulin syringe. Changing the BAC water volume proportionally changes the concentration and therefore the required draw volume. The calculator handles all unit conversions automatically—input your vial size, BAC water volume, and target dose, and it outputs the precise units to draw.